A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMS-986177 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs BMS 986177 (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 27 Jul 2017 Status changed from recruiting to completed.
- 12 Jul 2017 Planned End Date changed from 1 May 2017 to 23 Jul 2017.
- 12 Jul 2017 Planned primary completion date changed from 1 May 2017 to 22 Jul 2017.